uMotif Announces Validated eCOA/ePRO Interface
Study shows eCOA/ePRO interface is equivalent to responses from text-based smartphone formats.
Clinical eCOA/ePRO platform technology provider uMotif has released topline study results demonstrating its proprietary data capture interface incorporated into its eCOA/ePRO app offers a validated alternative to current text-based smartphone-based instruments for clinical, post-marketing and real-world research.
The independent quantitative equivalence study was conducted by SAFIRA Clinical Research at Dublin City University. Fifty-five participants completed testing in two randomized groups using the Motif visual interface and a traditional 5-point Verbal Response Scale (VRS-5). The study results showed equivalence between the Motif interface and standard VRS (high ICC) for capturing VRS data. Study results are expected to be published in 2023.
Bruce Hellman, Co-Founder and Chief Patient Officer expanded on the history of eCOA/ePRO to the significance of this study to Applied Clinical Trials. “Traditionally, PROs were paper, with a question at the top of the sheet, and patients would check one of the boxes [answers].” This same format migrated onto PDAs, then smartphones, but in the paper/text/content format. “We knew that patients found our app more engaging…it’s quicker to use, and it’s easier to use for different populations and age groups,” said Hellman. However, eCOA scientists have always asked that PROs could be validated from paper to PDAs, then PDAs to smartphones, now the equivalence of text-form smartphones to graphical user interfaces--the uMotif interface uses a flower-petal visual, with a finger-swipe indicator for responses.
Read more information on the study results.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
